Personalis

Personalis FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Personalis (PSNL) as of Oct 11, 2026 is 97.76 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 57.52 % — a change of 69.96% (higher).

FCF Conversion

97.76 %

YoY

69.96%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Personalis is 2025 97.76 % . FCF Conversion Rate (FCF/EBITDA) of Personalis was 2024 57.52 % . It decreases by 69.96% higher compared to the previous year.

The Personalis FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
11.47 USD
Jan 1, 2019
105.45 USD
Jan 1, 2020
111.19 USD
Jan 1, 2021
125.58 USD
Jan 1, 2022
106.01 USD
Jan 1, 2023
62.02 USD
Jan 1, 2024
57.52 USD
Jan 1, 2025
97.76 USD
The Personalis FCF Conversion history
YEARFCF ConversionYoY
97.76 %+69.96%
57.52 %-7.26%
62.02 %-41.49%
106.01 %-15.58%
125.58 %+12.94%
111.19 %+5.44%
105.45 %+819.72%
11.47 %-44.42%
20.63 %—
Access this data via the Eulerpool API

Personalis Stock analysis

What does Personalis do? Personalis Inc is a diagnostic company specializing in the development of tests for personalized medicine. The company was founded in 2011 by Dr. Richard Chen and Dr. Erin Newburn and is headquartered in Menlo Park, California. They initially focused on developing genomic tools for cancer diagnosis and treatment but have expanded their offerings to include tests for rare genetic diseases, immunotherapies, and precision oncology drugs. They work closely with pharmaceutical and biotechnology companies as well as academics to develop innovative therapeutic approaches. Their business model is based on making genomics biology usable for personalized medicine and clinical research. They have a wide portfolio of genomic-based solutions for personalized medicine, including tests for tumor mutations, tumor-specific neoantigens, rare genetic diseases, and personalized immunotherapy. They also offer customized genomic solutions for pharmaceutical and biotechnology companies. Personalis Inc aims to establish personalized medicine quickly and effectively to provide the best possible outcome for patients. Personalis is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Personalis stock

FCF Conversion Rate (FCF/EBITDA) of Personalis is 97.76 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Personalis changed from 57.52 % to 97.76 %, representing a 69.96% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Personalis since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Personalis with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

Cash Flow — Personalis

All Key Metrics — Personalis